Drug Profile
VX 759
Alternative Names: BCH-27759; VCH-759 (Polymerase NNI); VX-759Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Shire Pharmaceuticals Group
- Developer Vertex Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 01 May 2014 Discontinued - Phase-I for Hepatitis C (Monotherapy) in Canada (PO)
- 14 Sep 2011 Phase-I development is ongoing in Canada